We designed the synthesis of a small library of 3-substituted-3,6-diazabicyclo[3.1.1]heptanes whose affinity on neuronal nicotinic receptors (nAChRs) was evaluated. Among the synthesized compounds, the 5-(3,6-diazabicyclo[3.1.1]heptane-3-yl)-N-(2-fluorophenyl)nicotinamide 43 proved to be the most interesting compound with 42 Ki value of 10 pM and a very high7/42 selectivity. Furthermore, compounds 35, 39 and 43 elicited a selective partial agonist activity for 42 nAChR subtype.
Introduction
The activation of ionotropic acetylcholine nicotinic receptors (nAChRs) is responsible for several physiological processes; therefore, their modulation could be useful in the treatment of different pathological conditions [1] . Due to their potential therapeutic significance, in particular in the frame of the fight against tobacco addiction, nAChRs have been the subject of extensive researches that led to individuation of bridged piperazines (Figure 1) [2] derived from chemical modification of epibatidine, as unusual pharmacophore for nicotinic ligands [3] . (Fig. 1) showed high α4β2 affinity and a potent central analgesic activity in mouse hot plate paradigm, in analogy with that of epibatidine. Through theoretical calculations and high-field proton magnetic resonance ( 1 H-NMR) spectroscopy resulted that the tricyclic system of 1 has one conformation similar to that of epibatidine, responsible of the analogy in their pharmacological profile [4] .
In 2007 were reported the analgesic properties of a novel series of compounds, related to epibatidine, among which compound 2 (Figure 1) , typified by a 2,5-diazabicyclo[2.2.1]heptane structure, represents the best compound of the whole series [5] . Unfortunately, although endowed with analgesic activities in several animal models of neuropathic pain, its clinical evaluation was precluded, due to its unfavourable pharmacokinetic profile.
However, this new class of compounds served to hypothesize the common steric and electronic features useful to ensure the optimal interactions with nAChR α4β2 and α7, leading to identifying in 9 Finally, we incorporated the N-atom of the carboxamide moiety in a 1,2,3,4-tetrahydroquinoline- (46) or 1,2,3,4-tetrahydroisoquinoline-bicyclic system (47). This modification led to 42 affinity values of 196 pM and 31 pM, respectively. (Figure 5 ). The selectivity of these compounds was confirmed at the functional level, given that their agonist effects on human 34 nAChRs were visible only at high concentrations (>1 M),
with EC50 values >10 M (Figure 5 ). In particular, compound 39 was never able to elicit currents in GH4C1 cells expressing human 34 nAChRs. 
Molecular docking
To gain an insight into the possible binding modes for the compounds they were docked to the binding sites of both α4β2 and α7. The simulation showed a clear difference in the ligand positioning between the two subtypes. In the crystal structure of nAChR α7 epibatidine is shown to interact with multiple residues in the binding site, among them Leu106, Gln114, Tyr91 and most prominently an ionic interaction between the nitrogen of the azabicycloheptane moiety and Trp145 and Tyr191 (Figure 6A ). Similar interactions occur in the structure of the α4β2 subtype between the pyrrolidine nitrogen and Trp156 and Tyr204 (Figure 6B ). Compared to epibatidine the novel compounds (exemplary shown with compound 43) are turned around in in the binding pocket of the α7 subtype, since the bindig site is closed off on the side of the pyridyl and does not allow for larger 12 substitutions. This leads to a loss of the ionic interaction ( Figure 7A ). On the other hand, in the α4β2 subtype the compounds align with epibatidine and retain the ionic interaction. This could explain the high selectivity of the larger structures. and Tyr204 is retained and the core scaffold aligns with epibatidine.
Conclusions
A small library of 5-(3,6-diazabicyclo[3.1.1]heptan-3-yl)-N-arylnicotinamide derivatives have been designed. The 12 compounds synthesized and tested in this study, acting as partial agonists, allowed us to deepen the SARs on the 3,6-DBH core as template for the synthesis of potent nicotinic α4β2 receptor ligands, with Ki binding values better than epibatine for all series. The main structural features of whole DBH compounds, synthesized by us to today, are below summarized.
The initial synthesis of derivatives combining the 3,6-DBH system and various halo-pyridines (3, 4, 6 and 7) and a chloropiridazine (5) furnished compounds endowed with high α4β2 affinity and selectivity. This evidence let us to assume the halo-pyridine structure as lead compound and the 5'position of the pyridine ring as preferred for the modulation of this system, due to the interesting α4β2 binding values of agonists 6 and 7, (Ki α4β2 = 6.32 pM and 5.72 pM, respectively).
The modulation of C-5' aniline position with various substituted aryls, compounds typified by structure 11 (Ki α4β2 = 11.17 pM), displayed high α4β2 receptors affinity in accordance with that of halogenated homologues and very high selectivity values, the latter influenced by mono-phenyl substitution. Interestingly, the introduction of aryl rings on C-5' of pyridine nucleus exhibited α4β2 antagonist activity.
The introduction of an amine group between the heteroaromatic ring of the DBH system and the aryl ring gave three different classes of compounds, typified by compounds 9-11, resulting compounds of the 3-(anilino)pyridine series those with the high α4β2 Ki values ranging in the pM field (9, Ki α4β2 = 11.17 pM) and an affinity and selectivity slightly decreased with respect to the lead compound.
Finally, the introduction of the N-aryl nicotinamide function, allowed to identify the halo-aryl nicotinamides as the best derivatives of this series, resulting the compound 43 having a Ki α4β2 = 10 pM, similar to that of the lead compound of the whole DBH series.
In conclusion, tacking stock on 3,6-diazabicyclo[3.1.1]heptane ligands, we can conclude that the DBH-pyridine template represents a good pharmacophore for the design of nAChR ligands endowed with very high α4β2 affinity and selectivity, influenced by the nature of substituent on pyridine ring.
Indeed, even if all tested compound of different DBH series synthesized by us maintain high α4β2 affinity and selectivity, from our SARs emerged that the  or , both chlorine and bromine, substitution on the pyridine ring led to the best compounds of the DBH series with a very high affinity and selectivity for α4β2 nAChR subtype, better than epibatidine.
Experimental section

General procedures
The reactions involving air or moisture-sensitive compounds were performed under argon atmosphere. Unless otherwise specified, all materials, solvents, reagents and precursors were obtained from commercial suppliers and were used without further purification. 
To a solution of the Boc-bridged-piperazine 12 (200 mg, 1.00 mmol) [7] in dioxane (5 mL Reaction between 15 and benzylamine gave a crude product whose purification by plug chromatography (EtOAc) afforded 17. White solid; yield 94% (90 mg); mp 65-67 °C. 1 
N-(3-Chlorophenyl) 5-[6-(tert-butoxycarbonyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl]nicotine carboxamide (23)
Reaction between 15 and 3-chloroaniline gave a crude product whose purification by FC (chloroform/methanol 98:2) afforded 23. White solid; yield 85% (85 mg); mp 114 °C. 1 
N-(4-Chlorophenyl) 5-[6-(tert-butoxycarbonyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl]nicotine carboxamide (24)
Reaction between 15 and 4-chloroaniline gave a crude product whose purification by FC (chloroform/methanol 98:2) afford 24. White solid; yield 89% (89 mg); mp 130-132 °C. 1 
N-(2-Fluorophenyl) 5-[6-(tert-butoxycarbonyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl]nicotine carboxamide (25)
Reaction between 15 and 2-fluoroaniline gave a crude product whose purification by FC 
N-(4-Fluorophenyl) 5-[6-(tert-butoxycarbonyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl]nicotine carboxamide (27)
Reaction between 15 and 4-fluoroaniline gave a crude product whose purification by FC N-(1,2,3,4 
-Tetrahydroquinoline) 5-[6-(tert-butoxycarbonyl)-3,6-diazabicyclo[3.1.1]heptan-
3-yl]nicotine carboxamide (31)
Reaction between 15 and 1,2,3,4-tetrahydroquinoline gave a crude product whose purification by FC (petroleum ether/EtOAc 3:7) afforded 31. Beige solid; yield 55% (56 mg); mp 85-87 °C. 1 
General procedure for the preparation of final compounds 32-47.
The appropriate tert-butoxycarbonyl derivative (16 -31) (0.323 mmol) was dissolved in HCOOH (2 mL) and the solution was stirred at room temperature for 20 h. Then H2O was added and the acid solution was extracted with CHCl3. The aqueous layer was basified with 10% K2CO3 aqueous solution and extracted with CHCl3. The organic layer was dried (Na2SO4), filtered and concentrated under reduced pressure to afford the analytically pure product. The Ki (% of coefficient of variation) values shown were calculated by using the LIGAND program to fit the data obtained from at least three independent saturation and competition binding experiments for each compound using the α4β2, α3β4, and α7 subtypes.
5-(3,6-Diazabicyclo[3.1.1]heptane-3-yl)-N-(phenyl)nicotinamide (32)
Functional activity.
The electrophysiological measurements were made as previously described [8] .
Molecular docking.
The docking simulations were performed with GOLD version 5.2 (Cambridge Crystallographic Data Centre, Cambridge, UK). This program uses a genetic algorithm to calculate up to ten docking poses per input-ligand. GoldScore Fitness was selected as a scoring function, which takes hydrogen bonding, ligand internal strains, and steric aspects of the receptor-ligand complex into account.
Docking simulations were conducted on nAChR α4β2 and α7 subtypes. For the α7 subtype a crystal structure co-crystallized with epibatidine was available (PDB entry 3SQ6) [9] and used for docking.
A redocking was conducted to optimize the docking parameters and led to an RMSD of 1.18 with the final settings. In the course of the protein preparation, hydrogens were added. The binding site was defined in a 8 Å radius around the co-crystallized ligand of chain A.
For the α7 subtype a crystal structure co-crystallized with epibatidine was available (PDB entry 3SQ6) and used for docking. A redocking was conducted to optimize the docking parameters and led to an RMSD of 1.18 with the final settings. In the course of the protein preparation, hydrogens were added.
The binding site was defined in a 8 Å radius around the co-crystallized ligand of chain A.
